Pain Management

Special considerations for counseling patients and prescribing lasmiditan, a targeted 5-HT1F therapy approved as acute migraine treatment.

Timothy Smith, MD, RPh, FACP, AQH, describes goals of therapy for the acute treatment of migraine and reacts to current treatment limitations associated with available drug therapies.

Pharmacists should assess patient comorbidities, symptoms, and history to ensure the selection of the most appropriate migraine medication.

Amy R. Dunleavy, PharmD, highlights various drug therapies used for the acute treatment of migraine and provides recommendations for appropriate use.

A panel discussion regarding the underdiagnosis and burden of migraine attacks on patients and the rationale for educating the community about signs and symptoms.

A study comparing once-monthly injectable galcanezumab-gnlm with rimegepant has been planned to support the assessment of potential treatments to prevent migraines.

Patients who received non-opioid prescriptions were more likely to report having no pain in the first week after surgery than those who received opioids and both groups reported equal levels of satisfaction.

Technicians can help prevent drug diversion, provide care for patients with opioid use disorder.

Pharmacists play a role in prevention of opioid overdose by providing information to patients about signs and symptoms.

Although the opioid epidemic is a broad societal problem, health systems can play a critical role in the response.

Erenumab-aooe (Aimovig, Amgen) is indicated for the preventive treatment of migraine in adults, making it the first approved preventive migraine treatment of its kind.

Programs that provide ongoing support to patients with painful conditions and complex medication regimens may also help them avoid using opioid pain medications or reduce the amount that they use, according to a study published in Rheumatology and Therapy.

Finding the right medication or drug combination for individual patients is critical.

The percentage of patients who received an opioid among all ED visits during the 2018 shortage fell significantly from 11.5% pre-shortage to 8.5% during, and did not return to baseline once the shortage had ended.

Overdose rates were two and a half times higher among patients who filled an opioid prescription following a dental procedure.

Twenty percent of the pharmacies contacted indicated they would not dispense buprenorphine, with independent pharmacies and those in southern US states found significantly more likely to restrict the drug.

Study finds that cannabidiol (CBD) and expectancies for receiving CBD do not appear to reduce experimental pain intensity but do make the pain feel less unpleasant.

This is the first systematic literature review on the association of back pain and mortality.

Errors related to extended-release opioids and COVID-19 vaccines warrant attention and should be a priority.

Increased expansion and availability of naloxone may prove to be a monumental aspect of the public health response to the opioid crisis.

The FDA has approved the submission of a supplemental new drug application (sNDA) that expands the use of bupivacaine liposome injectable suspension to include patients aged 6 years and older for single-dose infiltration as a postsurgical local analgesia.

The study results reiterate the importance of interventions to lower prescribing rates of potentially inappropriate drugs among older adults.

Preliminary research by the American Heart Association suggests the opioid epidemic in the United States may have led to an increase in the number of strokes due to bacterial infections of the heart (infective endocarditis).

Pharmacy's History: German chemist Felix Hoffmann worked on the substances at Bayer during a 2-Week period in 1897.

Investigators found an average difference of 12% in the range of fracture-associated drug prescribing when comparing hospital referral regions.